In July the administration announced that generic drugs would carry a 100 percent tariff starting in August 2028, rising to 200 percent a year later, for companies that had not built American plants by then. A White House spokesman called it a two-year runway. The announcement came in a social media post and has not been followed by a proclamation, a Federal Register notice, a tariff schedule heading, or customs guidance. As of the customs schedule issued on September 28, generic drugs and their ingredients are dutiable at zero.
That gap between announcement and instrument is the whole story, and not because the policy is empty. The April proclamation that put 100 percent on patented drugs exempted generics explicitly and directed the Commerce Secretary to report within a year on whether action on generics is warranted. That report is not due until roughly April 2027. What exists now is a deadline without a rule, aimed at an industry with twenty-two months to respond.
What Is Actually in Force
The branded side is operating. Patented drugs and their active ingredients carry 100 percent, cut to 20 percent for a company with a Commerce-approved onshoring plan, which steps back up to 100 percent in April 2030. Japan, the European Union, South Korea and Switzerland are capped at 15 percent. A company holding both an onshoring plan and a most-favored-nation pricing agreement pays nothing until January 2029.
Generics sit outside all of that, at zero, under their own schedule heading. The qualifier in the official notice is three words: the tariffs do not apply to generic products and their ingredients, at this time.
The Mechanics of a Cost Increase With Nowhere to Go
Generic drugs are 89 to 91 percent of American prescriptions and about 11.6 percent of American drug spending. That ratio is the problem. The price of a generic is not set by its manufacturer. For hospital and clinic products it is fixed by group purchasing contracts that run one to three years, bind the manufacturer on price, and guarantee the buyer no volume. For Medicaid, a federal upper limit formula keys reimbursement to a backward-looking average of reported prices. A tariff arriving mid-contract has no route to the customer.
The government's own data show how little room there is. The Food and Drug Administration studied 163 drugs that went into shortage and found the median price beforehand was $8.73 a unit, that 63 percent were sterile injectables, and that the median drug had been approved nearly 35 years earlier. When supply collapsed, only 18 percent saw a sustained price increase of 50 percent or more, only 42 percent saw production rise, and only 30 percent recovered to pre-shortage supply. If total scarcity moves the price in fewer than one case in five, a cost shock will not move it either.
What Happens Instead
The manufacturer exits. The same study found that drugs heading into shortage represented 0.16 percent of their company's total revenue beforehand, with revenues already falling 12.9 percent a year. A product that is sixteen hundredths of one percent of the business and shrinking is not one anyone fights for. The cheaper response to a new cost is to stop making it, or to drop the awkward strengths and small vial sizes while keeping the profitable one.
There is usually nobody to replace it. Roughly 40 percent of American generic markets have one manufacturer and the median market has two. Pharmacists tracked 225 active shortages in the third quarter, with 87 new ones through September against 89 in all of 2025. One industry count found discontinuations rising from 106 in 2024 to 170 in 2025.
The reshoring arithmetic does not close either. Congressional testimony puts a new plant at three to ten years and repurposing existing capacity at one to two. Only about 24 percent of the ingredient facilities serving the American market sit in the United States, and 83 percent of the top hundred generics have no domestic ingredient source. Verifiable generic-specific investment commitments here total roughly $1.25 billion, against something near $240 billion announced on the branded side. The schedule already gives a zero rate to products made with American ingredients, and that incentive has not moved generic production home.
What It Looks Like at the Counter
A guidance memo the Medicare agency wrote in 2009 still governs what happens next. When a formulary generic is unavailable, drug plans need not charge the cost sharing of the missing drug and may apply brand or non-formulary cost sharing to the substitute, and the substitution is not a formulary exception, so it can be withdrawn when supply returns. A shortage reaches a beneficiary not as an empty shelf but as a higher tier on a drug she did not choose, under a rule written seventeen years ago for a benefit that has since been redesigned twice. Part D's $2,100 out-of-pocket cap limits the damage in 2026 and also means she reaches it sooner.
— John Stone